Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer`s Disease

Study:

A Phase 2a Multi-center, Randomized, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of T-817MAa in Patients With Mild to Moderate Alzheimer`s Disease

Rationale:

n/a

Purpose:

The primary objective of the study is to evaluate the efficacy of T-817MA in AD patients to treat dementia. Efficacy will be cognitive function, as measured by the ADAS-cog cognitive assessment. The secondary objectives of the study are to evaluate the safety of T-817MA and the activities of daily living (assessed with the ADCS-ADL) of AD patients taking T-817MA, and to evaluate the efficacy of T-817MA in AD patients with an overall global assessment using the ADCS-CGIC.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Alzheimer`s Disease Drug: T-817MA
Drug: Placebo
Phase 2

Verified by Toyama Chemical Co., Ltd. December, 2012

Sponsored by: Toyama Chemical Co., Ltd.
Information provided by: Toyama Chemical Co., Ltd.
ClinicalTrials.gov identifier: NCT00663936

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic - Lou Ruvo Center for Brain Health
Las Vegas, Nevada 89106
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site